Reshma is the kind of leader who can deliver that extraordinary future—it only seems crazy because no one’s done it before. I ...

The Synthetic Biology Market is valued at USD 16.94 Billion in 2024 and is expected to reach USD 167.98 Billion by 2035 at a ...

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

AI-driven drug discovery firms rallied on Friday after the U.S. Food and Drug Administration (FDA) announced an initiative to ...

Certara’s AI strategy and FDA-aligned offerings fuel growth across drug discovery and trials, with expanding margins. Read ...

The FDA is phasing out animal testing for monoclonal antibody therapies, embracing AI and human-based models. Read more here.

The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the ...

Ginkgo Bioworks (DNA) announced a new contract with the Advanced Research Projects Agency for Health, or ARPA-H, alongside partners Tritica ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...

The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

Ginkgo Bioworks (DNA) is down -4.8%, or -27c to $5.39.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...